August 17, 2012

Bosentan in heart transplantation candidates with severe pulmonary hypertension: efficacy, safety and outcome after transplantation.


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Bosentan is an orally administered dual endothelin-receptor antagonist that has proven effective in therapy for pulmonary arterial hypertension (PAH). Severe PAH as confirmed by increased pulmonary vascular resistance (PVR), is associated with increased right ventricular failure and mortality after heart transplantation. In this prospective study, the authors administered bosentan to patients considered high-risk candidates for heart transplantation because of high PVR. They found that therapy with bosentan seemed to be associated with a significant reduction in PVR, to a transplantable range, and with a good outcome after transplantation.

Cardiac Transplantation

Tags: , ,